A Canadian-led team of scientists has discovered a new antibiotic hidden within a decades-old bacterium, offering hope in the fight against drug-resistant infections. The study, led by Gerry Wright, reveals that the new drug, named 'manikomycin,' could pave the way for a unique class of treatments.
Discovery of Manikomycin
The research team, based at McMaster University in Hamilton, Ontario, uncovered the antibiotic while re-examining a bacterium originally isolated in the 1970s. The bacterium, known as Streptomyces, had been stored in a freezer for decades. Using advanced genomic and chemical analysis, the scientists identified a previously overlooked compound with potent antibacterial properties.
How Manikomycin Works
Manikomycin targets a specific enzyme in bacteria that is essential for cell wall synthesis. This mechanism is distinct from most existing antibiotics, making it effective against strains that have developed resistance to other drugs. In laboratory tests, manikomycin successfully killed methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Implications for Treatment
Gerry Wright, a professor at McMaster University and the study's lead author, emphasized the significance of the discovery. 'Manikomycin represents a new class of antibiotics that could be developed into treatments for some of the most dangerous drug-resistant infections,' he said. The compound is still in early stages, but the team plans to conduct further tests to assess its safety and efficacy in animal models before moving to human trials.
Addressing the Antibiotic Crisis
The discovery comes at a critical time. The World Health Organization has declared antibiotic resistance a global health emergency, with drug-resistant infections causing over 1.5 million deaths annually. New antibiotics are urgently needed, but few are in development due to economic and scientific challenges.
Future Research
The Canadian team is now working to synthesize manikomycin in the lab to enable larger-scale production. They are also exploring whether the compound can be modified to enhance its activity and reduce potential side effects. 'This is just the beginning,' Wright added. 'We hope to have clinical trials within the next five years.'
The study was published in the journal Nature Biotechnology and funded by the Canadian Institutes of Health Research and the Ontario Research Fund.
